Document series
Trial abstracts — page 3
700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.
Showing 0 records on this page
Trial records
700 documents · page 3 of 30
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| STEP-TEENS | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 201 | 2022 | Moderate |
| SURMOUNT-1 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 2,539 | 2022 | High |
| SURPASS-5 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 475 | 2022 | High |
| AMPLITUDE-O | Exenatide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 4,076 | 2021 | Moderate |
| CAGRI-PH2-DOSEFIND | Cagrilintide | Phase 2 | Reported | Dose-finding | 706 | 2021 | Moderate |
| STEP-1 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 1,961 | 2021 | High |
| STEP-2 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 1,210 | 2021 | High |
| STEP-3 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 611 | 2021 | High |
| STEP-4 | Semaglutide | Phase 3 | Reported | Randomised withdrawal | 803 | 2021 | High |
| SURPASS-1 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 478 | 2021 | High |
| SURPASS-2 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, active-controlled | 1,879 | 2021 | High |
| SURPASS-3 | Tirzepatide | Phase 3 | Reported | Randomised, open-label, active-controlled | 1,444 | 2021 | High |
| SURPASS-4 | Tirzepatide | Phase 3 | Reported | Randomised, open-label, active-controlled | 2,002 | 2021 | High |
| AWARD-11 | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, active-controlled | 1,842 | 2020 | High |
| SCALE-TEENS | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 251 | 2020 | Moderate |
| TED-PAEDIATRIC | Teduglutide | Phase 3 | Reported | Single-arm open-label | 59 | 2020 | Moderate |
| ELAM-PH2-HFPEF | SS-31 (elamipretide) | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 71 | 2019 | Low |
| PIONEER-1 | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 703 | 2019 | High |
| PIONEER-6 | Semaglutide, oral | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 3,183 | 2019 | High |
| RECONNECT-301 | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 626 | 2019 | Moderate |
| RECONNECT-302 | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 630 | 2019 | Moderate |
| REWIND | Dulaglutide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 9,901 | 2019 | High |
| TESA-NAFLD-PH2 | Tesamorelin | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 61 | 2019 | Low |
| AWARD-7 | Dulaglutide | Phase 3 | Reported | Randomised, open-label, active-controlled | 576 | 2018 | Low |
page 3 of 30